1-20 of 66
Eyal C. Attar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults

Philip C. Amrein, Eyal C. Attar, Geoffrey G Fell, Traci M. Blonquist, Andrew M. Brunner, Gabriela S. Hobbs, Hanno R. Hock, Steven McAfee, Rupa Narayan, Jenna A. Moran, Meghan Bergeron, Julia E. Foster, Christina Bertoli, Kristin McGregor, Meghan Burke, Tanya T. Behnan, Tina T. Som, Aura Y. Ramos, Megan K. Vartanian, Jennifer Lombardi Story, Donna S. Neuberg, Amir T. Fathi
Journal: Blood
Blood (2022) 140 (Supplement 1): 3309–3311.
https://doi.org/10.1182/blood-2022-160100
Published: 2022
Journal Articles

Phase I and Expansion Study of Eprenetapopt (APR-246) in Combination with Venetoclax (VEN) and Azacitidine (AZA) in TP53 -Mutant Acute Myeloid Leukemia (AML)

Guillermo Garcia-Manero, Aaron D Goldberg, Eric S. Winer, Jessica K. Altman, Amir T. Fathi, Olatoyosi Odenike, Gail J. Roboz, Phillip Gallacher, Anders Wennborg, Denice Kaylor Hickman, Eyal C. Attar, David A. Sallman
Journal: Blood
Blood (2021) 138 (Supplement 1): 3409.
https://doi.org/10.1182/blood-2021-148940
Published: 2021
Journal Articles

Phase II Trial of Eprenetapopt (APR-246) in Combination with Azacitidine (AZA) As Maintenance Therapy for TP53 Mutated AML or MDS Following Allogeneic Stem Cell Transplantation (SCT)

Asmita Mishra, Roni Tamari, Amy E. DeZern, Michael T. Byrne, Mahasweta Gooptu, Yi-Bin Chen, H. Joachim Deeg, Phillip Gallacher, Anders Wennborg, Denice Kaylor Hickman, Eyal C. Attar, Hugo F. Fernandez
Journal: Blood
Blood (2021) 138 (Supplement 1): 409.
https://doi.org/10.1182/blood-2021-147962
Published: 2021
Journal Articles

Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

David A. Sallman, Rami S. Komrokji, Amy E. DeZern, Marie Sebert, Guillermo Garcia-Manero, Ramy Rahmé, David P. Steensma, Jacqueline Lehmann che, Gail J. Roboz, Isabelle Madelaine, Mikkael A. Sekeres, Pierre Peterlin, Kendra Sweet, Odile Beyne Rauzy, Andrew T. Kuykendall, Christian Recher, Amy F McLemore, Aspasia Stamatoullas, Ling Zhang, Lise Willems, Qianxing Mo, Emmanuel Raffoux, Lisa Nardelli, Celine Berthon, Najla Al Ali, Bruno Quesnel, Eric Padron, Greg Korbel, Eyal C. Attar, Hagop Kantarjian, Alan F. List, Lionel Ades, Jeffrey E. Lancet, Pierre Fenaux, Thomas Cluzeau
Journal: Blood
Blood (2021) 138 (Supplement 1): 246.
https://doi.org/10.1182/blood-2021-153286
Published: 2021
Journal Articles

Longitudinal Molecular Profiling in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib

Sung Choe, PhD, Hongfang Wang, PhD, Gail J. Roboz, MD, Courtney D. DiNardo, MD MSCE, Eytan M. Stein, MD, Alice S. Mims, MD, Gabrielle T. Prince, MD, Justin M. Watts, MD, Bin Fan, PhD, Parham Nejad, BSc, Vickie Zhang, PhD, Hua Liu, PhD, Eyal C. Attar, MD, Bin Wu, PhD, Richard M. Stone, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–3.
https://doi.org/10.1182/blood-2020-136589
Published: 2020
Journal Articles

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults

Philip C. Amrein, MD, Eyal C. Attar, MD, Geoffrey Fell, Traci M. Blonquist, MS, Andrew M. Brunner, Gabriela S. Hobbs, MD, Hanno R. Hock, MD PhD, Steven L. McAfee, MD, Rupa Narayan, MD, Jenna A. Moran, NP, Meghan Bergeron, NP, Julia E. Foster, NP, Christina Bertoli, NP, Kristin McGregor, Molly Macrae, Meghan Burke, Tanya T. Behnan, BS, Tina T. Som, RN, Aura Y. Ramos, RN, Megan K. Vartanian, RN, Jennifer Lombardi Story, Donna S. Neuberg, ScD, Amir T. Fathi
Journal: Blood
Blood (2020) 136 (Supplement 1): 7–8.
https://doi.org/10.1182/blood-2020-140584
Published: 2020
Journal Articles

Phase 1 and Dose Expansion Study of APR-246 in Combination with Ibrutinib or Venetoclax-Based Therapy in Subjects with TP53 -Mutant Relapsed and/or Refractory Non-Hodgkin Lymphomas (NHL) Including Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)

Meghan C. Thompson, MD, Matthew S. Davids, MD, Nitin Jain, MD, Jacob D. Soumerai, MD, Praveen Ramakrishnan Geethakumari, MD MS, Amy Gubits, MPH, Denice Hickman, RN, Anders Wennborg, MD PhD, Eyal C. Attar, MD, Omar Abdel-Wahab, MD, Anthony R. Mato, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 15–16.
https://doi.org/10.1182/blood-2020-139022
Published: 2020
Journal Articles

Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls

Peter Paschka, MD, Hervé Dombret, MD, Xavier Thomas, MD PhD, Christian Recher, MD PhD, Sylvain Chantepie, MD, Pau Montesinos Fernandez, MD PhD, Evelyn Acuña-Cruz, MD, Paresh Vyas, MRCP, FRCP, FRCPath, Karl-Anton Kreuzer, MD, Michael Heuser, Klaus H. Metzeler, MD, Michael Dennis, MD, Bruno Quesnel, MD PhD, Mathilde Hunault-Berger, MDPhD, Mohamad Mohty, MD PhD, Arnaud Pigneux, MD PhD, Stephane De Botton, Daniela Weber, MSc, Konstanze Döhner, Gary Milkovich, PharmD, John Reitan, PharmD, Sarah C MacDonald, SD, Deborah Casso, MPH, Michael Storm, MSc, Hua Liu, PhD, Stephanie M. Kapsalis, BS, Eyal C. Attar, MD, Thomas Winkler, MD, Hartmut Döhner, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-136957
Published: 2020
Journal Articles

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1 -mutant acute myeloid leukemia

Clinical Trials & Observations
Gail J. Roboz, Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton, Alice S. Mims, Gabrielle T. Prince, Jessica K. Altman, Martha L. Arellano, Will Donnellan, Harry P. Erba, Gabriel N. Mannis, Daniel A. Pollyea, Anthony S. Stein, Geoffrey L. Uy, Justin M. Watts, Amir T. Fathi, Hagop M. Kantarjian, Martin S. Tallman, Sung Choe, David Dai, Bin Fan, Hongfang Wang, Vickie Zhang, Katharine E. Yen, Stephanie M. Kapsalis, Denice Hickman, Hua Liu, Samuel V. Agresta, Bin Wu, Eyal C. Attar, Richard M. Stone
Journal: Blood
Blood (2020) 135 (7): 463–471.
https://doi.org/10.1182/blood.2019002140
Published: 2020
Includes: Supplemental data
Journal Articles

Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1 -Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Analyses

Hongfang Wang, PhD, Sung Choe, PhD, Courtney D. DiNardo, MD MSc, Eytan M. Stein, MD, Stéphane de Botton, MD PhD, Amir T. Fathi, MD, Martin S. Tallman, MD, Hagop M. Kantarjian, MD, Richard M. Stone, MD, Lynn Quek, MD PhD, Vickie Zhang, PhD, Hua Liu, PhD, Eyal C. Attar, MD, Bin Wu, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 541.
https://doi.org/10.1182/blood-2019-122703
Published: 2019
Journal Articles

Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1 -Mutant Relapsed or Refractory Acute Myeloid Leukemia

Sung Choe, PhD, Hongfang Wang, PhD, Courtney D. DiNardo, MD MSc, Eytan M. Stein, MD, Stephane De Botton, Amir T. Fathi, MD, Martin S. Tallman, MD, Hagop M. Kantarjian, MD, Richard M. Stone, MD, Lynn Quek, MD PhD, Zenon Konteatis, PhD, Lenny Dang, PhD, Vickie Zhang, PhD, Hua Liu, PhD, Eyal C. Attar, MD, Bin Wu, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 545.
https://doi.org/10.1182/blood-2019-122671
Published: 2019
Journal Articles

Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

David A Sallman, MD, Amy E. DeZern, MD, Guillermo Garcia-Manero, MD, David P. Steensma, MD, Gail J. Roboz, MD, Mikkael A. Sekeres, MD MS, Thomas Cluzeau, MD PhD, Kendra L. Sweet, MD, Amy F McLemore, M.S., Kathy McGraw, PhD, John Puskas, PhD, Ling Zhang, MD, Jiqiang Yao, PhD, Qianxing Mo, PhD, Lisa Nardelli, Najla Al Ali, M.Sc, Eric Padron, MD, Greg Korbel, PhD MBA, Eyal C. Attar, MD, Hagop M. Kantarjian, MD, Jeffrey E. Lancet, MD, Pierre Fenaux, MD PhD, Alan F. List, MD, Rami S. Komrokji, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 676.
https://doi.org/10.1182/blood-2019-131055
Published: 2019
Journal Articles

Ivosidenib (AG-120) in Patients with IDH1 -Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

James M. Foran, MD, Courtney D. DiNardo, MDMSc, Justin M. Watts, MD, Eytan M. Stein, MD, Stephane De Botton, Amir T. Fathi, MD, Gabrielle T. Prince, MD, Anthony Stein, MD, Richard M. Stone, MD, Prapti A. Patel, MD, Martin S. Tallman, MD, Sung Choe, PhD, Hongfang Wang, PhD, Vickie Zhang, PhD, Bin Fan, PhD, Katharine E. Yen, PhD, Abdulafeez Oluyadi, PharmD, Thomas Winkler, MD, Denice Hickman, BSN, Samuel V. Agresta, MD, Hua Liu, PhD, Bin Wu, PhD, Eyal C. Attar, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4254.
https://doi.org/10.1182/blood-2019-123946
Published: 2019
Journal Articles

Molecular remission and response patterns in patients with mutant- IDH2 acute myeloid leukemia treated with enasidenib

Clinical Trials & Observations
Eytan M. Stein, Courtney D. DiNardo, Amir T. Fathi, Daniel A. Pollyea, Richard M. Stone, Jessica K. Altman, Gail J. Roboz, Manish R. Patel, Robert Collins, Ian W. Flinn, Mikkael A. Sekeres, Anthony S. Stein, Hagop M. Kantarjian, Ross L. Levine, Paresh Vyas, Kyle J. MacBeth, Alessandra Tosolini, Jason VanOostendorp, Qiang Xu, Ira Gupta, Thomas Lila, Alberto Risueno, Katharine E. Yen, Bin Wu, Eyal C. Attar, Martin S. Tallman, Stéphane de Botton
Journal: Blood
Blood (2019) 133 (7): 676–687.
https://doi.org/10.1182/blood-2018-08-869008
Published: 2019
Includes: Supplemental data
Journal Articles

Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Myeloid Leukemia in Older Adults

Philip C. Amrein, MD, Eyal C. Attar, MD, Traci M. Blonquist, MS, Andrew M. Brunner, MD, Gabriela S. Hobbs, MD, Hanno Hock, MD PhD, Steven McAfee, MD, Jenna A. Moran, NP, Meghan Bergeron, Julia Foster, ANP, Christina Bertoli, Kristin McGregor, Molly Macrae, Meghan Burke, Tanya T. Behnan, BS, Tina T. Som, RN, Aura Y. Ramos, Megan K. Vartanian, RN, Jennifer Lombardi Story, Donna S Neuberg, ScD, Amir T. Fathi, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4059.
https://doi.org/10.1182/blood-2018-99-117566
Published: 2018
Journal Articles

Population Pharmacokinetics of Ivosidenib (AG-120) in Patients with IDH1-Mutant Advanced Hematologic Malignancies

Kha Le, PhD, Russ Wada, PhD, David Dai, PhD, Bin Fan, PhD, Guowen Liu, PhD, Hua Liu, PhD, Eyal C. Attar, MD, Samuel V. Agresta, MD, Hua Yang, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1394.
https://doi.org/10.1182/blood-2018-99-109863
Published: 2018
Journal Articles

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study

Gail J. Roboz, MD, Courtney D. DiNardo, MDMSc, Eytan M. Stein, MD, Stephane de Botton, MD PhD, Alice S. Mims, MD, Gabrielle T. Prince, MD, Jessica K. Altman, MD, Martha L. Arellano, MD, William B. Donnellan, MD, Harry P. Erba, MD PhD, Gabriel N. Mannis, MD, Daniel A Pollyea, MD, Anthony S. Stein, MD, Geoffrey L. Uy, MD, Justin M. Watts, MD, Amir T. Fathi, MD, Hagop M. Kantarjian, MD, Martin S. Tallman, MD, Sung Choe, PhD, David Dai, PhD, Bin Fan, PhD, Hongfang Wang, PhD, Vickie Zhang, PhD, Katharine E. Yen, PhD, Stephanie M. Kapsalis, OTR, Denice Hickman, RN, Hua Liu, PhD, Samuel V. Agresta, MD, Bin Wu, PhD, Eyal C. Attar, MD, Richard M. Stone, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 561.
https://doi.org/10.1182/blood-2018-99-110595
Published: 2018
Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study

Celalettin Ustun, MD, Jennifer Le-Rademacher, PhD, Hai-Lin Wang, MPH, Megan Othus, Zhuoxin Sun, PhD, Brittny Major, Mei-Jie Zhang, PhD, Elizabeth Storrick, Jacqueline M Lafky, Selina Chow, Krzysztof Mrózek, MD PhD, Eyal C. Attar, MD, Clara D. Bloomfield, MD, Larry D Cripe, MD, Richard A. Larson, MD, Guido Marcucci, Gail J. Roboz, MD, Geoffrey L. Uy, MD, Richard M. Stone, MD, Aminah Jatoi, Thomas C. Shea, MD, Marcos de Lima, MD, James M. Foran, MD, Brenda M. Sandmaier, MD, Mark R. Litzow, MD, Harry P. Erba, MD PhD, Arti Hurria, MD, Daniel J. Weisdorf, MD, Andrew S Artz, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2170.
https://doi.org/10.1182/blood-2018-99-118383
Published: 2018
Journal Articles

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from a Phase 1 Dose Escalation and Expansion Study

Courtney D. DiNardo, MDMSc, Justin M. Watts, MD, Eytan M. Stein, MD, Stephane de Botton, MD PhD, Amir T. Fathi, MD, Gabrielle T. Prince, MD, Anthony S. Stein, MD, James M. Foran, MD, Richard M. Stone, MD, Prapti A. Patel, MD, Martin S. Tallman, MD, Sung Choe, PhD, Hongfang Wang, PhD, Vickie Zhang, PhD, David Dai, PhD, Bin Fan, PhD, Katharine E. Yen, PhD, Stephanie M. Kapsalis, OTR, Denice Hickman, RN, Samuel V. Agresta, MD, Hua Liu, PhD, Bin Wu, PhD, Eyal C. Attar, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1812.
https://doi.org/10.1182/blood-2018-99-111264
Published: 2018
Journal Articles

Genetic Profiling and Deep IDH1 Mutation Clearance to ≤0.04% in Ivosidenib (AG-120)-Treated Patients with Mutant IDH1 Relapsed or Refractory and Untreated AML

Richard M. Stone, MD, Sung Choe, PhD, Vickie Zhang, PhD, Benoit Marteyn, PhD, Virginie Penard-Lacronique, PhD, Hongfang Wang, PhD, Courtney D. DiNardo, MDMSc, Eytan M. Stein, MD, Amir T. Fathi, MD MD BS, Martin S. Tallman, MD, Hagop M. Kantarjian, MD, Eyal C. Attar, MD, Bin Wu, Stephane de Botton, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2684.
https://doi.org/10.1182/blood.V130.Suppl_1.2684.2684
Published: 2017